RT Journal Article
SR Electronic
T1 Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.08.21261769
DO 10.1101/2021.08.08.21261769
A1 Henriquez, S.
A1 Zerbit, J.
A1 Bruel, T.
A1 Ouedrani, A.
A1 Planas, D.
A1 Deschamps, P.
A1 Staropoli, I.
A1 Hadjadj, J.
A1 Varet, B.
A1 Suarez, F.
A1 Ermark, N.
A1 Bouscary, D.
A1 Willems, L.
A1 Fouquet, G.
A1 Decroocq, J.
A1 Franchi, P.
A1 Deau-Fischer, B.
A1 Terrier, B.
A1 Tamburini, J.
A1 Chatenoud, L.
A1 Schwartz, O.
A1 Vignon, M.
YR 2021
UL http://medrxiv.org/content/early/2021/08/09/2021.08.08.21261769.abstract
AB Multiple myeloma (MM) patients are at risk of fatal outcome after SARS-CoV-2 infection. Preliminary data suggest that MM patients have an impaired response to vaccination. This prospective study analyzed the humoral and cellular immune responses to two doses of BNT162b2 in 72 MM patients, including 48 receiving anti-CD38 immunotherapy. Results evidenced that MM patients display lower levels of SARS-CoV-2 specific IgG and IgA antibodies and decreased neutralization of alpha and delta variants when compared to healthy controls. They also showed decreased numbers of circulating IFNγ-producing Spike SARS-CoV-2 specific T lymphocytes. This defective immune response was particularly marked in patients receiving anti-CD38 immunotherapy. Furthermore, a retrospective investigation of MM patients among COVID-19-related death in the Paris area suggested a limited efficacy of BNT162b2 in patients treated with anti-CD38. Overall, these results show a decreased immunogenicity of BNT162b2 in MM patients and stress the need for novel strategies to improve SARS-CoV-2 prophylaxis in immunocompromised individuals.Competing Interest StatementT.B., I.S. and O.S. are coinventors on provisional patent no. US 63/020,063 entitled "S-Flow: a FACS-based assay for serological analysis of SARS-CoV-2 infection" submitted by Institut Pasteur. Clinical Trial2021-A02124-37Funding StatementWork in OS lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Medicale, ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2 and IDISCOVR. DP is supported by the Vaccine Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the institutional review board of Cochin Hospital (CLEP number: AAA-2021-08041).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.